PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTivozanib
Tivozanib
Fotivda (tivozanib) is a small molecule pharmaceutical. Tivozanib was first approved as Fotivda on 2017-08-24. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3, vascular endothelial growth factor receptor 2, and vascular endothelial growth factor receptor 1.
Download report
Favorite
FDA Novel Drug Approvals 2021
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
fotivdaNew Drug Application2025-05-23
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TIVOZANIB HYDROCHLORIDE, FOTIVDA, AVEO PHARMS
2026-03-10NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Tivozanib Hydrochloride, Fotivda, Aveo Pharms
115043652039-11-05U-3476
68219872024-04-26DS, DPU-3100
71667222023-11-16DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EK: Vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitors
— L01EK03: Tivozanib
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—111——2
CarcinomaD002277—C80.0111——2
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTivozanib
INNtivozanib
Description
1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea is an aromatic ether.
Classification
Small molecule
Drug classangiogenesis inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Identifiers
PDB—
CAS-ID475108-18-0
RxCUI—
ChEMBL IDCHEMBL1289494
ChEBI ID—
PubChem CID9911830
DrugBankDB11800
UNII ID172030934T (ChemIDplus, GSRS)
Target
Agency Approved
FLT1
FLT1
Organism
Homo sapiens
Gene name
FLT1
Gene synonyms
FLT, FRT, VEGFR1
NCBI Gene ID
2321
Protein name
vascular endothelial growth factor receptor 1
Protein synonyms
FLT, FLT-1, fms related tyrosine kinase 1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor
Uniprot ID
P17948
Mouse ortholog
Flt1 (14254)
vascular endothelial growth factor receptor 1 (P35969)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,179 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,861 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use